This is a first time in human study to assess the safety and tolerability of AZD1979 following oral administration of single ascending doses in healthy male volunteers. Pharmacokinetics (what the body does to the drug) parameters will also be assessed as secondary objectives.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
116
Single dose, oral solution administration
Single dose, oral solution administration
Research Site
Overland Park, Kansas, United States
Safety variables in terms of: Adverse events, clinical laboratory variables, vital signs, electrocardiograms and telemetry, physical examinations, and assessments of anxiety and mood
Time frame: Up to 62 days
Pharmacokinetics of AZD1979 assessed by means of plasma concentration analyses
Time frame: up to 48 hours post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.